Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chan

Showing results (1421-1430 of 1,535) with videos related to

Pageof 154
Sort By:
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Cancer Research|May 14, 2009
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancerSabine C Glöckner, Mashaal Dhir, Joo Mi Yi, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Plos One|August 29, 2018
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsAlice L Yuan, Christian B Ricks, Alexandra K Bohm, et al.
NPJ Biofilms and Microbiomes|April 8, 2024
Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinomaLiuyang Cai, Hengyan Zhu, Qianqian Mou, et al.
Nature Cancer|January 2, 2026
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancerNadeem Riaz, Tyler J Alban, Robert I Haddad, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Journal of the National Cancer Institute|May 31, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meetingSimron Singh, Thomas A Hope, Emily B Bergsland, et al.
Pageof 154

Showing results (1421-1430 of 1,535) with videos related to

Sort By:
Pageof 154
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Cancer Research|May 14, 2009
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancerSabine C Glöckner, Mashaal Dhir, Joo Mi Yi, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Plos One|August 29, 2018
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsAlice L Yuan, Christian B Ricks, Alexandra K Bohm, et al.
NPJ Biofilms and Microbiomes|April 8, 2024
Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinomaLiuyang Cai, Hengyan Zhu, Qianqian Mou, et al.
Nature Cancer|January 2, 2026
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancerNadeem Riaz, Tyler J Alban, Robert I Haddad, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Journal of the National Cancer Institute|May 31, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meetingSimron Singh, Thomas A Hope, Emily B Bergsland, et al.
Pageof 154